


U.S. LEADERSHIP IN BIOTECHNOLOGY

Biotechnology: Fueling Innovation and Job Creation, Transforming Care

The U.S. produces more new drugs than the rest of the world combined*




Percentages do not add up to 100% due to rounding.

U.S. bioscience firms employ 1.7 million people in communities across the country.**

*Source: Milken Institute; Xconomy, "Which Countries Excel in Creating New Drugs? It's Complicated" 2014; Kneller, Nature Biotechnology, 2012

**Source: "The Value of Bioscience Innovation in Growing Jobs and Improving Quality of Life 2016" BIO/TEconomy (includes health care, agriculture and industrial and environmental jobs)

U.S. is well-positioned for future innovation



Source: BioMedTracker, BIO Industry Analysis

U.S. LEADERSHIP IN BIOTECHNOLOGY

Effective Public Policy is Critical to Maintaining Leadership and Long-Term Success

To maintain U.S. leadership, the policy and regulatory environment needs to keep pace with innovations happening in labs across the country. The only thing that can impede long-term U.S. biotechnology leadership is short sighted policy proposals that stifle innovation and scare away investment. Entrepreneurs and investors need policy certainty to be successful at the incredibly difficult task of drug development, where more than 90% of endeavors fail.

THE U.S. HAS...



Brilliant scientists



Savvy entrepreneurs



World-class research institutions



Investors willing to commit the capital needed to fund medical innovation

THE U.S. NEEDS TO MAINTAIN...



An efficient and predictable regulatory review process



Transparent payment systems that reward innovation and encourage free-market competition



Continued advancement and funding of scientific understanding



Strong intellectual property (IP) rights and a reliable system for IP transfer, licensing, and collaboration

“

Creating new drugs through biotechnology is at the risky end of a business in which superhuman stamina and bottomless pockets are minimum requirements.

— *The Economist Magazine*

”